In a clinical trial in pediatric patients aged 12 years with normal baseline heart rate, more patients treated with Wegovy injection compared to placebo had maximum changes in heart rate of 20 bpm or more (54% vs 39%)
There was no difference between tirzepatide, semaglutide and placebo regarding risk for serious adverse events
The most common ones were: More predictable periods: 45% of all respondents and 64% of those with PCOS More frequent periods: 21% of all respondents and 23% of those with PCOS Shorter periods: 19% of all respondents and 20% of those with PCOS When looking at these results, its worth noting that other factors can impact the menstrual cycle too, and its difficult to separate which cycle changes are specifically due to the GLP-1 medications
By adopting a comprehensive, patient-focused approach that involves careful assessment, vigilant monitoring, and a commitment to addressing individual needs, healthcare providers can help patients harness the benefits of semaglutide while minimizing its drawbacks
What are some risks and side effects of using semaglutide
Most clinical studies use twice-daily dosing [1]
